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Abstract Immune-mediated rejection of human cancer is a
relatively rare but well-documented phenomenon. Its rate of
occurrence progressively increases from the occasional
observation of spontaneous regressions to the high rate of
complete remissions observed in response to effective treat-
ments. For two decades, our group has focused its interest in
understanding this phenomenon by studying humans follow-
ing an inductive approach. Sticking to a sequential logic, we
dissected the phenomenon by studying to the best of our
capabilitybothperipheralandtumorsamplesandreachedthe
conclusion that immune-mediated cancer rejection is a facet
ofautoimmunitywherethetargettissueisthecanceritself.As
we are currently deﬁning the strategy to effectively identify
the mechanisms leading in individual patients to rejection of
their own tumors, we considered useful to summarize the
thoughtprocessthatguidedustoourowninterpretationofthe
mechanisms of immune responsiveness.
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CTA Cancer testing antigen
FNA Fine needle aspiration biopsy
HLA Human leukocyte antigen
ICR Immunologic constant of rejection
IEFs Immune effector genes
IFN Interferon
IL Interleukin
IRF Interferon regulatory factor
ISGs Interferon-stimulated genes
MDA Melanoma differentiation antigens
SLE Systemic lupus erythematosus
STAT-1 Signal transducer and activator of transcription
TIL Tumor inﬁltrating lymphocyte
TA Tumor antigen
TSD Immune-mediated tissue-speciﬁc destruction
The molecular basis of T cell-mediated immune
recognition and the self–non-self preposition
The ﬁrst evidence that T cells can recognize cancer was
based on the description by Wolfel et al. [1] of tumor
inﬁltrating lymphocytes (TILs) that could kill autologous
tumor cells following a human leukocyte antigen (HLA)-
restricted pattern and by Kawakami et al. [2] who char-
acterized the requirements for HLA restriction. In 1991, the
molecular characterization of the ﬁrst tumor antigen (TA)
recognized by T cells was done by Van der Bruggen
et al. [3]. This discovery, followed by the identiﬁcation or
several other TA-speciﬁc molecular targets of T cells [4,
5], provided the opportunity for tumor-speciﬁc immuno-
therapeutic intervention [6]. Contemporaneously, others
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TAs of which several were also recognized by T cells
[7].
One category of TAs included melanoma differentiation
antigens (MDA) whose expression is shared by melanoma
cells and normal epithelial melanocytes. Another category
includes proteins whose expression was associated with the
progressive de-methylation of cancer cells; as these non-
mutated proteins were expressed selectively by germ line
cells in the testes and cancer cells, they were named cancer
testing antigens (CTA).
The identiﬁcation of MDAs and CTAs and their
respective epitopes associated with speciﬁc HLA mole-
cules spurred interest in using these molecules and their
derivatives for TA-speciﬁc active immunization [8]. An
increasing body of literature has more recently focused on
TA derived from infectious agents such as human papil-
loma virus or immunogenic mutated proteins whose
expression may or may not be shared by different
patients’ tumors depending upon the frequency of a given
mutation. These TAs may represent a distinct and
important facet of T cell-mediated recognition of tumors.
Indeed, recent work suggests that immunization against
viral antigens may be particularly promising [9]. The
current viewpoint represents a retrospective evaluation of
what we learnt predominantly studying MDA-speciﬁc
vaccinations; we believe that part of the learning may
apply to a broader range of phenomena related to T cell-
based immunotherapy of cancer while in other cases,
more immunogenic non-self TA may stand on their own.
Future work should include of course these approaches
for which at the moment there is relatively less clinical
experience.
Epitope-speciﬁc anti-cancer vaccines as a model
to understand immune rejection
Despite the large number of trials vaccinating patients with
TAs, results have been in general disappointing [8, 10, 11],
although in a minority of cases, vaccines may prolong the
frequency of clinical responses and/or survival [12–14].
One of them is now the ﬁrst anti-cancer vaccine licensed by
the Food and Drug Administration. Independent of their
clinical potential, epitope-speciﬁc anti-cancer vaccines,
however, provided to immunologists the unprecedented
opportunity to study in relatively controlled settings how
the human immune system functions. Thus, it could be
tested whether vaccine-induced circulating TA-speciﬁc T
cells could reach the tumor site and recognize their target
[15]; the use of tetrameric HLA complexes [16] made it
possible to characterize ex vivo the functional properties of
vaccine-induced T cells [17, 18].
The paradoxical co-existence of tumor-speciﬁc T cells
(in the circulation and in the tumor) and their target
Anti-cancer vaccination efforts consistently elicited
expansion of TA-speciﬁc memory T cells in the peripheral
circulation, but this was rarely accompanied by cancer
regression [19], suggesting that tumor rejection is a com-
plex phenomenon that goes beyond the recognition of
target cells by T cells [20]. Several questions emerged: do
vaccine-induced T cells reach the tumor site? Does the
tumor microenvironment provide sufﬁcient co-stimulation
to activate otherwise quiescent T cells [21]? How do the
evolving phenotypes of cancer cells escape potentially
effective immune responses? Most intriguingly, are tumor-
changing phenotypes responsible for cancer cell escape
from recognition by an adequately activated immune
response? Alternatively, are the immune responses elicited
by vaccines insufﬁcient to destroy cancer cells that are
otherwise adequately expressing target molecules [21]?
The quiescent status of vaccine-induced T cell
Lee et al. [22] documented a status of anergy of sponta-
neously occurring MDA-speciﬁc circulating T cells. Fur-
ther work demonstrated that, beyond stage II, patients with
breast and colon cancer or melanoma suffer a profound
depression of innate immune responses. This immune
suppression is exempliﬁed by reduced production of IFN-c
in response to TA-speciﬁc stimulation ex vivo [22] and
reduced inducible levels of signal transducer and activator
of transcription (STAT)-1 phosphorylation in circulating
immune cells following ex vivo stimulation with type I
interferon (IFN) [23, 24]. Interestingly, it was observed that
although patients with cancer experience a signiﬁcantly
reduced responsiveness to IFN-a stimulation compared
with healthy individuals, such depression occurs within a
big range of values with some patients demonstrating
normal response to stimulation also at a later stage of
disease. This suggests that some aspects of the host’s or the
individual tumor biology may differ dramatically among
different cancer-bearing subjects. Similar ﬁndings were
later reported by others, who observed in patients with
cancer the same depression in STAT-1 phosphorylation
following stimulation with IL-2 [25]. It also became
apparent that spontaneously occurring anti-cancer immune
responses in patients with metastatic melanoma displayed a
memory phenotype [26, 27] providing evidence for in vivo
priming of effector T cells by the cancer-bearing status
[26].
While the work of Lee and other groups focused on
spontaneously occurring TA-speciﬁc T cells, others ana-
lyzed the type and function of vaccine-elicited T cells
762 Cancer Immunol Immunother (2012) 61:761–770
123documenting that naturally occurring TA-speciﬁc immune
responses could be consistently enhanced by immunization
[28, 29]. Contrary to naturally occurring TA-speciﬁc T
cells incapable of expressing IFN-c in response to cognate
stimulation [22], vaccine-induced T cells were able to
produce IFN-c ex vivo [17]. However, they lacked cyto-
toxic function that could be recovered by in vitro activation
with TA-speciﬁc stimulation in the presence of recombi-
nant interleukin (IL)-2. We deﬁned these incompletely
anergic vaccine-induced T cells as ‘‘quiescent’’ [18]. This
quiescent phenotype was reminiscent of the contraction
phase of effector immune responses described by Kaech
[30] according to the linear model of T cell activation.
According to this model, following a time-delimited
stimulation, T cells expand and become activated during
the ﬁrst week, acquiring also cytotoxic properties. In the
following 2–3 weeks, CD8 T cells contract in number and,
while maintaining responsiveness to antigen-speciﬁc
stimulation, loose cytotoxic function. This model well
approximates the kinetics of TA-speciﬁc immunization,
which is provided at intervals of 1–3 weeks, and T cell
immune responses are generally tested weeks after immu-
nization. This observation raised the question: assuming
that vaccine-induced T cells reach the tumor site, could the
tumor in steady state conditions or during immune therapy
provide a milieu conducive to their reactivation comparable
to that simulated in vitro by re-stimulation with TA in the
presence of IL-2 [18]? While most remained interested in
the afferent aspects of vaccination and continued to
develop increasingly more sophisticated strategies aimed at
inducing qualitatively and quantitatively better immune
responses, we turned our interest toward the efferent loop
to understand the requirements for their activation in the
target organ. This was based on the assumption that cir-
culating vaccine-induced T cells were fully functional
according to the physiology and the dynamics of T cell
activation in response to a time-limited stimulus such as a
vaccine [21]. It should be clariﬁed that the afferent aspect
of immunization include mode of action studies and the
pharmacodynamics that are integral part of a rational
development of immune therapies aiming at inducing
speciﬁc immune responses while the efferent aspect
includes the study of those variables that determine the
effects of vaccine-induced immune responses after their
induction. It should also be emphasized that the study of
the afferent loop of tumor vaccines remains important for
drug developers aiming to understand the mechanism of
action of their products; many basic questions remain
unsolved (which antigen format, which adjuvant, which
route of administration, which dosing schedule, etc.). Thus,
although drug developers made in the past the mistake of
concentrating mostly on the afferent loop neglecting the
efferent one, we should not make the reverse mistake now
but rather combine the two approaches into an integrated
and systematic analysis of all potential variables that could
decode the algorithm governing immune responsiveness.
The limited role of tumor immune escape as predictor
of immune responsiveness
Evolution under selection implies that forceful negative
pressure is imposed upon malleable phenotypes. To explain
the co-existence of a cognate immune response against
cancer with its concurrent growth, immune selection is
often invoked [31, 32]. This concept revolves around the
demonstration in experimental and clinical models that
immune suppression is associated with higher incidence of
spontaneous cancers [33, 34]. Recently, this concept is
enjoying broader clinical recognition as the relevance of
immune inﬁltrates on the natural history of cancer is
becoming increasingly appreciated [35, 36]. To explain
why tumors grow in the presence of an active immune
response, the work of several groups including ours has
described and characterized several potential mechanisms
by which tumors could escape immune recognition [20, 32,
37–39]. However, these observations refer to conditions
when tumors do not undergo immunotherapy and a balance
is stricken between the host’s immune response and cancer
growth. Therefore, it is likely that immune escape, also
referred to as immune editing [40], may play a signiﬁcant
role at the onset and throughout the natural history of
cancer. However, to establish causation in the determinism
of responsiveness to immunotherapy, level of TA and TA
presentation should be assessed before treatment and a
predictive relationship should be demonstrated on the
likelihood to respond to the respective treatment. In fact,
the balance stricken between the host’s immune response
and its cancer in natural conditions is shaken by powerful
immune responses observable during an acute inﬂamma-
tory process [41]. Thus, the described mechanism that
could explain reduced recognition of tumor cells in natural
conditions may not apply to the lack of tumor respon-
siveness to effective immunotherapy when the balanced is
switched suddenly in favor of the host, and cancer cells had
no time to adapt to the novel condition. As later described,
direct human observations of tumors performed before
treatment did not demonstrate that the level of TA
expression predicts response to therapy. Those studies
suggested that the lack of response to immunotherapy is
due to limited activation of immune responses within the
target organ rather than the loss of antigenic properties by
cancer cells. Loss of TA expression appears only after
treatment in recurring lesions following partially successful
therapy that did not completely eradicate all cancer cells
[20] (Fig. 1).
Cancer Immunol Immunother (2012) 61:761–770 763
123On the necessity to study the tumor microenvironment
and the serial biopsy strategy
Direct observation of the tumor microenvironment may
obviate for the need of hypotheses [42, 43]. As TSD is
tissue-speciﬁc, it is best to study the target organ: the
cancer itself. There is a dissonance between the current
emphasis on the characterization of circulating immune
cells and the indirect role that they play in the cancer
microenvironment. The approach lacks appreciation for the
heterogeneity of individual tumors and their dynamic
instability [44]. Thus, to understand human cancer immune
responsiveness, tumors should be studied in steady state
conditions to document patient-speciﬁc idiosyncrasies and
during therapy to discover phenomena relevant to TSD. It
should be kept in mind that immune manipulation of the
host may not only effect the function of immune cells but,
directly or indirectly, the function also of cancer cells or
other normal cells within the tumor microenvironment. It is
only during those dynamic moments that the mechanisms
relevant to rejection will emerge; only at those moments,
modulation of HLA expression [45–48] or changes in
cytokines-dependent modulation of the immune microen-
vironment become apparent as well as exempliﬁed by the
dual role played by IL-10 that will be discussed later [49].
Thus, we conclude that tumor-related TSD could be
effectively studied by catching the switch from a chronic to
an acute inﬂammatory process by serially studying indi-
vidual tumors before, during, and after treatment [50].
It soon became apparent, however, the classical
approaches to the study of tumors were not suitable. Most
studies utilized excisional biopsies, which provide optimal
quantity of tissue and allow its morphological assessment.
However, because the tumor is removed, serial sampling of
AC
Cancer Cells
CTL
NK Cell
Macrophage
Antibody
Adaptive killing
Innate killing
DAMP
DAMP
Dead cell debris
Epitope +
Epitope loss
BD
Fig. 1 Extremes in the interpretation of the mechanisms leading to
tumor rejection and their impact on the relevance of the heterogeneity
of tumor cells in determining their escape from immune recognition.
a In the simplest scenario, adaptive immune responses, whether
mediated by cytotoxic T cells (CTLs) or antibody-mediated cytotox-
icity, play a prominent role in eliminating cancer cells expressing the
appropriate epitope; in a cancer population with heterogeneous
expression of target epitope due to loss of antigen or antigen
processing and presentation defects, only the epitope expressing
cancer cells would be eliminated leaving the other ones alive (b).
c An alternative scenario suggests that the effector/target cell complex
may deliver pro-inﬂammatory signals due to the release of cytokines
or damage-associated molecular patterns (DAMPs; in the ﬁgure, in
red are those associated with T cell effector function, in blue those
associated with antibody-mediated cytotoxicity). These, in turn,
attract and activate innate immune effectors such as natural killer
(NK) cells or macrophages which can exert cytotoxic functions on
cancer cells independent of epitope expression. This, in turn, may
lead to a broader clearance of cancer cells leaving only macrophages
in charge of tissue repair (d). Which of these scenarios more closely
represent human reality remains to be determined
764 Cancer Immunol Immunother (2012) 61:761–770
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Moreover, no direct correlation can be performed between
the ﬁndings obtained studying the excised material and the
response to immunotherapy of concomitant metastases left
in the patient. The assumption that removed tumors are
representative of those left in the patient as targets of
therapy was soon proved inaccurate; the study of syn-
chronous metastases demonstrated signiﬁcant variability
among most markers evaluated [51]. We, therefore, applied
in subsequent studies minimally invasive biopsies such as
ﬁne needle aspirate (FNA) biopsies that allowed serial
sampling of the same lesions [50].
Localization of vaccine-induced T cells at tumor site
may be necessary but it is not sufﬁcient for tumor
regression
Localization within tumors of indium
111-labeled adoptively
transferred TILs is necessary for clinical response [52];
however, TIL localization is not sufﬁcient, and several
lesions demonstrating uptake do not respond to therapy.
Since TIL localization in the target organ is necessary
for tumor rejection, we tested whether vaccine-induced T
cells reached the tumor site. Kammula et al. [15] applied
serial FNAs to melanoma metastases, comparing the
expression of interferon (IFN)-c before and during vacci-
nation. This study was performed on lesions whose cancer
cells did express sufﬁcient amount of the relevant HLA
allele to exclude escape from T cell recognition; expression
of the MDA target of the vaccination was monitored in
parallel. Furthermore, localization of vaccine-speciﬁc T
cells was monitored with tetrameric HLA/peptide com-
plexes. This study clearly documented a signiﬁcant
enhancement in IFN-c expression in tumors following
vaccination, and the level of expression of this cytokine
correlated with the level of expression of the relevant
MDA. Thus, vaccine-induced T cell do reach the tumor
site, interact with tumor cells by producing IFN-c and,
therefore, are not anergic. However, this functionally
competent localization was not sufﬁcient for tumor rejec-
tion as all lesions continued to grow. This ﬁnding mirrors
the quiescent phenotype of vaccine-induced T cells
observed in the circulation that could produce IFN-c when
encountering the relevant TA but cannot exert broader
effector functions.
The surprising role of IL-10
Several studies suggest that tumors produce immune reg-
ulatory molecules that could suppress the function of T
cells. Applying FNA biopsies, we assessed in pre-treatment
samples the expression of cytokines with potential regu-
latory effects [53]. Surprisingly, the expression levels of
none of them predicted unresponsiveness; on the contrary,
higher levels of IL-10 signiﬁcantly predicted response.
Further analyses demonstrated that the IL-10 was not only
expressed at the RNA but also at the protein level by cancer
cells. Retrospectively, this observation was not surprising
as several other studies had observed that, contrary to the
expectations, IL-10 overexpression was a predictor of
immune responsiveness. This cytokine probably favors
tumor growth in steady state conditions by inhibiting the
maturation of antigen presenting cells, but at the same
time, sustaining their ability for antigen uptake and
simultaneously hampering their migration to draining
lymph nodes prepares antigen presenting cells to serve as
powerful T cell stimulators loaded with TA when the
microenvironmental conditions are altered during immune
stimulation that could affect a switch of their phenotype by
the presence of immune stimulatory cytokines such as IFN-
c and TNF-a that could induce their maturation in situ [49].
Levels of HLA/TA expression by cancer cells does
not predict immune response
It is logical that the success of TA-speciﬁc vaccination is
predicated upon the level of expression of the target TA by
cancer cells. We, therefore, measured by FNA in pre- and
post-treatment metastases the expression of TA relevant
and irrelevant to the vaccine administered [54]. The anal-
ysis included only melanoma metastases whose cancer
cells expressed the associated HLA molecule necessary for
T cell recognition. The level of expression of the target TA
was not predictive of responsiveness. However, we
observed that lesions biopsied soon after treatment as they
were undergoing a biological response that subsequently
led to their complete disappearance dramatically reduced
the expression of the TA target of the vaccine. This
observation suggests that when immunotherapy works, the
ﬁrst targets of therapy are the cancer cells expressing the
relevant TA. The loss of TA expression was not associated
with complete disappearance of cancer cells at that time
point as other TA expressed speciﬁcally by cancer cells
such as CTAs were still present, and cancer cells could still
be observed in the cytospins. Thus, loss of cancer cells
expressing TA targeted by the vaccine preceded the elim-
ination of the complete neoplastic population. Since the
metastases subsequently underwent complete disappear-
ance, it became clear that the effect of vaccination was to
initiate a self-perpetuating process that continued beyond
the initial interaction between vaccine-induced T cells
and their targets [20, 55]. The same conclusion was
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text of CTA-speciﬁc anti-cancer vaccination [56].
The advent of whole-genome, hypothesis-generating
studies
The dynamic approach to the study of immune respon-
siveness had, by the end of the 1990s, crushed several
myths. Hundreds of modulatory mechanisms that could
hamper immune responsiveness could be postulated but
such number was too high to be realistically tackled by
future studies with a minimalistic approach. Around that
time, whole-genome transcriptional assays enter the scene
of clinical investigation [57]. The hypothesis-generating
strategy well suited our lack of a dominant hypothesis and
proved invaluable for the application of an inductive
approach aimed at decoding the multifactorial algorithm
governing tumor immune responsiveness [41, 43, 50, 55,
58–60]. In particular, we became interested in character-
izing two phenomena: ﬁrst, document the mechanism of
tumor rejection by sampling lesions during and after
treatment and comparing those that eventually responded
to those that did not. Second, dissect the reasons why some
but not all tumors respond to identical treatments.
The pre-determinism of immune responsiveness
The ﬁrst attempt to address at the whole genome level the
determinism leading to tumor rejection was an analysis of
melanoma metastases biopsied before and after treatment
with TA-speciﬁc vaccination and concomitant systemic
administration of IL-2 [45]. Analysis of pre-treatment
biopsies identiﬁed a set of genes differentially expressed by
lesions that subsequently responded to treatment. Although
those early array platforms contained few immunologically
relevant genes, the transcripts that differentiated respond-
ing from non-responding metastases had predominantly
immune function. This observation leads to the conclusion
that some metastases were pre-determined to respond to
immunotherapy by a pre-existing inﬂammatory process
that although not sufﬁcient to induce spontaneous tumor
regression was conducive to immune stimulation. A decade
later, we could validate in a small prospective mechanistic
study these ﬁndings [47]: pre-treatment biopsies in patients
with metastatic melanoma who subsequently responded to
systemic IL-2 administration displayed a pre-existing pro-
inﬂammatory status. Simultaneously, others identiﬁed
similar signatures to be predictive of responsiveness in
patients with melanoma vaccinated with four TAs plus IL-
12 [61], dendritic cells loaded with multiple TAs [62], or
melanoma and lung cancer patients receiving a MAGEA3
peptide vaccine [63].
Similarity between cancer rejection and other aspects
of immune-mediated tissue-speciﬁc destruction (TSD)
Inaseparatestudy,weevaluatedthemechanismofactionof
systemic IL-2 administration by sampling melanoma
metastases before and during treatment. This study demon-
strated that the mechanism of action of IL-2 is an indirect
activation of macrophages mediated by a cytokine storm
released by circulating IL-2 receptor-bearing cells [64]. The
effects at the tumor site were the degrees of magnitude less
than at the systemic level. Moreover, the intra-tumor effects
were delayed, and the magnitude was dose dependent. This
could explain why immune responsiveness has been asso-
ciated with number of doses received by patients [65].
Because one of the lesions from the six patients studied
underwent clinical response, we had the ﬁrst glimpse at the
transcriptional machinery speciﬁc for tumor rejection [64].
Surprisingly,severalofthetranscriptsexpressedspeciﬁcally
by the responding lesion had been simultaneously described
by another group as markers of acute kidney allograft
rejection [66]. This was the ﬁrst suggestion that tumor
regression, allograft rejection, and probably other immune
destructiveprocesseswere facets ofacommonphenomenon
that shared a convergent ﬁnal pathway.
From the delayed allergy reaction to the immunologic
constant of rejection (ICR)
In 1969, Jonas Salk [67] hypothesized that allograft
rejection, tumor rejection, and various autoimmune phe-
nomena represented facets of a similar immune-mediated
phenomenon that he called the ‘‘delayed allergy reaction’’.
His intuition was validated decades later by work from
those who studied with high throughput technology tissue
undergoing TSD. This unbiased approach applied to acute
allograft rejection, tissues affected by graft versus host
disease or ﬂare of autoimmunity, acutely infected organs
undergoing clearance of pathogen and tumor rejection
during immunotherapy identiﬁed a convergent pathway
and a group of genes that were always required for TSD to
occur. We named this signature ‘‘the immunologic constant
of rejection (ICR)’’ [55]. The ICR includes at least 4
functional components: the activation of (1) the IFN-c/
STAT1/IRF-1 pathway [41], (2) immune effector mecha-
nisms, (3) CXCR3, and (4) CCR5 ligand chemokines [68].
How deﬁning the ICR guided the understanding
of immune responsiveness
The ICR axiom describes how TSD occurs independent of
its cause; in other words, the ICR dictates ‘‘how’’ but not
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necessary pathway clariﬁed the premises for the identiﬁ-
cation of its causes. It became clear that the lack of
rejection of tumors during immunotherapy is due to
insufﬁcient stimulation of immune responses at the tumor
site rather than to the escape of tumors from a fully acti-
vated immune response. Analysis of patients with mela-
noma experiencing a mixed responses [48] and comparison
of tumors responding and non-responding to the same
treatment [45, 47] demonstrated that while responding
tumors displayed a strongly activated acute inﬂammatory
status, non-responding ones were completely immunolog-
ically silent as if the treatment had not reached the target
tissue. Moreover, the deﬁnition of the ICR leads to the
conclusion that genes and pathways activated during TDS
are qualitatively similar to those associated with a good
prognostic connotation in various cancers [35, 36, 69] and
to those predicting immune responsiveness to distinct type
of immunotherapy [45, 47, 61, 63, 70]. Thus, a general
theory of rejection could be constructed, whereby a pro-
gression occurs in the host versus cancer relationship,
starting with immune surveillance that slows but does not
abrogate tumor growth to a pre-determinism to respond to
therapy to a full blown activation of the immune response
leading to cancer rejection during treatment. Similar sig-
natures are observed throughout this continuum but the
intensity and breath of their activation increases progres-
sively till TDS is reached.
A genetic inference on human cancer immune
responsiveness; the role of the genetic background
of the host, neoplastic instability, and external factors
Perhaps, the most important contribution offered by the
ICR concept in deconvoluting the determinism of tumor
rejection is the provision of a road map deﬁned by evi-
dence-based hypotheses. Identiﬁcation of a speciﬁc group
of genes, whose activation is necessary for TSD, leads to
the analysis of the role of IRF5 polymorphism in mela-
noma immune responsiveness. This study was based on the
premise that, if the ICR applies to autoimmunity and if
cancer rejection represents an aspect of autoimmunity,
genes relevant to the development of autoimmunity ought
to inﬂuence the immune biology of cancer. IRF5 plays a
signiﬁcant role in the modulation of several autoimmune
diseases including systemic lupus erythematosus (SLE).
We recently observed that the same polymorphisms pro-
tective against the development of SLE predict non-
response to adoptive transfer of TILs (unpublished own
data). Similarly, appreciation for the central role played by
the CXCR3/CCR5 cluster in mediating TSD leads us to the
investigation of its expression by TILs. Integration of germ
line, transcriptional, and protein expression data brought to
the formulation of a protein prediction model strongly
predictive of treatment outcome (unpublished own data). It
is important to note that in this study, the expression of
individual receptors was not highly predictive of immune
responsiveness but the combined over- or underexpression
was strongly pointing to the need to look at the biomarkers
of immune responsiveness not as individual entities but in
accordance with their combined function. Importantly, this
second-generation, evidence-based, and hypothesis-driven
studies enlightened an underappreciated fault of current
bioinformatics approaches applied to the identiﬁcation of
biomarkers of immune responsiveness. This study dem-
onstrated that individual, univariate approaches bear, when
examined individually, very little predictive value but the
combination of factors integrated according to a logical
stream may progressively break the code governing the
algorithm of immune responsiveness.
The genetics of the host, the tumor,
and the environment
The relative weight played by the host’s genetic back-
ground, the somatic alterations acquired during the neo-
plastic process, and the inﬂuence of environmental factors
in determining immune responsiveness is unclear. Obser-
vations performed during the last two decades strongly
suggest that it is a combination of the three that determine
immune responsiveness [60]. It is likely that inherited
genetic factors may affect the biology of the host or their
cancer cells to determine the likelihood of immune
responsiveness; to this ﬁrst checkpoint, the genetics of
cancer cells may add its own predisposition to being sus-
ceptible to immune attack. Finally, various undetermined
variables encompassing the effectiveness of treatment,
general status of health and other ‘‘hidden’’ external factors
may contribute to the ﬁnal outcome. Only when all
checkpoints are permissive, tumor rejection is observed.
Moreover, the genetic weight that the host’s background
plays on tumor biology is often underestimated. Tumors
from individual patients are close to each other biologically
when compared to those from other patients; this may not
only be due to their clonal derivation as often assumed [71,
72], but it could also depend upon the innumerable poly-
morphisms inherited by cancer cells from their host. Thus,
the genetic background of the host may affect immune
responsiveness, not only by affecting the function of nor-
mal immune cells but also by directly affecting the biology
of cancers cells. This multistep inference on the mecha-
nism of immune responsiveness may also explain why it is
generally easier to predict accurately lack of responsive-
ness than responsiveness; it is necessary to have a gun to go
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but having a gun is not sufﬁcient as ability to shoot, good
visibility, presence of ducks, and many other limiting
factors may determine the success of the hunt.
The future challenges and opportunities
In the same manuscript where the delayed allergy reaction
was described, Jonas Salk [67] also stated: ‘‘The answers
pre-exist and are the questions that need to be identiﬁed’’.
We totally agree. The algorithm governing tumor response
to immunotherapy is lying in front of us. The recipe to its
identiﬁcation is simple: ﬁrst, study the tumor together with
the peripheral circulation; second, study the genetic back-
ground of the host together with the genetics of the tumor;
third, apply integrative bioinformatics approaches search-
ing for complex relationships rather than univariate class
comparisons. We are conﬁdent that this recipe will soon
lead to the understanding of tumor immune responsiveness
with a caveat: we need to sensitize those who design
clinical trials to the need to learn from clinical investiga-
tions rather than limiting the testing to the clinical endpoint
[73].
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